Media Coverage

See which leaders are on the move across the pharma, biotech and medical marketing industries.

Labviva, a Boston-based AI startup that streamlines procurement for the life sciences industry, is launching a London office, the company tells Axios.

CEO Siamak Baharloo said the uncertainty around tariffs and global supply chains make now an important moment for Labviva to expand its presence.

To meet today’s environmental and operational demands, labs must rethink procurement—leveraging technology and supplier diversity to cut waste and strengthen supply chains

Empower lower-level decision makers to be responsive to shifts in the supply chain. It is commonplace to centralize decision-making higher up in the organization regarding supply chain management. This is historically due to prime supplier strategies where negotiations are best done in a consolidated format. By implementing better technologies throughout the supply chain and leveraging marketplace systems, decisions can be decentralized and pushed downstream. I have worked with companies throughout the life sciences space that have successfully tapped into the savings that this decentralization can create, and they have seen hard cost savings of around 20% over more centralized models. Those levels of savings can mitigate the impacts of tariffs and provide more options to work around them.

Labviva has launched its automated inventory management system (IMS) to enable laboratory scientists, researchers, and procurement professionals to work in real time by streamlining inventory management of external suppliers and internal supplies of a shared organizational inventory or stock room. The company says lab managers can track shipments, access AI-driven operational recommendations across 15 million SKUs and 8,000 manufacturers, and increase efficiencies using AI-driven replenishment.

The disruptions of recent years serve as a powerful reminder: a resilient supply chain is not just a competitive advantage—it’s a necessity for advancing global health.

Backed by 53 Stations and key investors, Labviva aims to revolutionize supply chain transparency and accelerate scientific innovation with cutting-edge artificial intelligence solutions.Backed by 53 Stations and key investors, Labviva aims to revolutionize supply chain transparency and accelerate scientific innovation with cutting-edge artificial intelligence solutions.

Labviva, an AI-powered procurement platform for life sciences, secured $25M in Series B funding led by 53 Stations, bringing its total funding to $55M, to drive product innovation, expand internationally, and enhance customer support.